These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

193 related items for PubMed ID: 33822480

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. CNS progression during vinblastine or targeted therapies for high-risk relapsed ALK-positive anaplastic large cell lymphoma: A case series.
    Ruf S, Hebart H, Hjalgrim LL, Kabickova E, Lang P, Steinbach D, Schwabe GC, Woessmann W.
    Pediatr Blood Cancer; 2018 Jun; 65(6):e27003. PubMed ID: 29512859
    [Abstract] [Full Text] [Related]

  • 3. Isolated central nervous system (CNS) relapse in a case of childhood systemic anaplastic large cell lymphoma without initial CNS involvement.
    Mori T, Sugita K, Kimura K, Fuke T, Miura T, Kiyokawa N, Fujimoto J.
    J Pediatr Hematol Oncol; 2003 Dec; 25(12):975-7. PubMed ID: 14663283
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Isolated Central Nervous System Progression During Systemic Treatment With Brentuximab Vedotin Monotherapy in a Pediatric Patient With Recurrent ALK-negative Anaplastic Large Cell Lymphoma.
    Kim Y, Sudo A, Oyama R, Keino D, Tomizawa D, Kato M, Osumi T, Mori T.
    J Pediatr Hematol Oncol; 2021 Aug 01; 43(6):e864-e866. PubMed ID: 32769561
    [Abstract] [Full Text] [Related]

  • 6. Brentuximab Vedotin and High-dose Methotrexate Administrated Alternately for Refractory Anaplastic Large-cell Lymphoma With Central Nervous System Disease.
    Mitsunobu T, Nishikawa T, Kusuda M, Nakagawa S, Kodama Y, Okamoto Y, Kawano Y.
    J Pediatr Hematol Oncol; 2020 Aug 01; 42(6):e456-e458. PubMed ID: 31274669
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Advances in the treatment and prognosis of anaplastic lymphoma kinase negative anaplastic large cell lymphoma.
    Wang X, Wu J, Zhang M.
    Hematology; 2019 Dec 01; 24(1):440-445. PubMed ID: 31072226
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. The biology and management of systemic anaplastic large cell lymphoma.
    Hapgood G, Savage KJ.
    Blood; 2015 Jul 02; 126(1):17-25. PubMed ID: 25869285
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Correlation of the autoantibody response to the ALK oncoantigen in pediatric anaplastic lymphoma kinase-positive anaplastic large cell lymphoma with tumor dissemination and relapse risk.
    Ait-Tahar K, Damm-Welk C, Burkhardt B, Zimmermann M, Klapper W, Reiter A, Pulford K, Woessmann W.
    Blood; 2010 Apr 22; 115(16):3314-9. PubMed ID: 20185586
    [Abstract] [Full Text] [Related]

  • 13. Anaplastic large cell lymphoma, ALK-negative.
    Ferreri AJ, Govi S, Pileri SA, Savage KJ.
    Crit Rev Oncol Hematol; 2013 Feb 22; 85(2):206-15. PubMed ID: 22789917
    [Abstract] [Full Text] [Related]

  • 14. Brain metastasis of ALK positive anaplastic large cell lymphoma after a long-term disease free survival in an old adult.
    Wang CX, Wang H, Li J, Ma HH, Yu B, Shi SS, Zhou XJ, Shi QL.
    Int J Clin Exp Pathol; 2014 Feb 22; 7(3):1182-7. PubMed ID: 24696735
    [Abstract] [Full Text] [Related]

  • 15. ALK- anaplastic large-cell lymphoma is clinically and immunophenotypically different from both ALK+ ALCL and peripheral T-cell lymphoma, not otherwise specified: report from the International Peripheral T-Cell Lymphoma Project.
    Savage KJ, Harris NL, Vose JM, Ullrich F, Jaffe ES, Connors JM, Rimsza L, Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO, Weisenburger DD, International Peripheral T-Cell Lymphoma Project.
    Blood; 2008 Jun 15; 111(12):5496-504. PubMed ID: 18385450
    [Abstract] [Full Text] [Related]

  • 16. ALK expression plays different roles in anaplastic large-cell lymphomas and outcome of crizotinib use in relapsed/refractory ALK+ patients in a Chinese population.
    Huang L, Zhang F, Zeng J, Guo H, Liu S, Wei X, Chen F, Jiang X, Liang Z, Liu Y, Li W.
    Ann Hematol; 2018 Jan 15; 97(1):149-159. PubMed ID: 29150811
    [Abstract] [Full Text] [Related]

  • 17. Anaplastic large cell lymphoma, ALK-positive.
    Ferreri AJ, Govi S, Pileri SA, Savage KJ.
    Crit Rev Oncol Hematol; 2012 Aug 15; 83(2):293-302. PubMed ID: 22440390
    [Abstract] [Full Text] [Related]

  • 18. CD8 expression in anaplastic large cell lymphoma correlates with noncommon morphologic variants and T-cell antigen expression suggesting biological differences with CD8-negative anaplastic large cell lymphoma.
    Shen J, Medeiros LJ, Li S, Wang SA, Lin P, Khanlari M, Iyer SP, Yin CC, Tang G, Jorgensen JL, Hu S, Miranda RN, Xu J.
    Hum Pathol; 2020 Apr 15; 98():1-9. PubMed ID: 32032618
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinicopathological features and prognostic significance of programmed death ligand 1 in pediatric ALK-positive anaplastic large cell lymphoma: results of the ALCL99 treatment in Japan.
    Iwafuchi H, Nakazawa A, Sekimizu M, Mori T, Osumi T, Iijima-Yamashita Y, Ohki K, Kiyokawa N, Fukano R, Saito AM, Horibe K, Kobayashi R, Lymphoma Committee and Pathology Committee of the Japanese Pediatric Leukemia/Lymphoma Study Group.
    Hum Pathol; 2021 Oct 15; 116():112-121. PubMed ID: 34363798
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.